major breakthrough is on the horizon for Crohn's disease
December 1997
A major breakthrough is on the horizon for Crohn's disease.
A new biotech drug is expected next year...called Avakine (infliximab) by Centocor.
Avakine is a monoclonal antibody that blocks tumor necrosis factor...and therefore, slows inflammation.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote